The genetically modified pig pig heart is implanted in a human for the first time

News: For the first time, the heart of a pig is implanted in a person. A man with a heart condition called David Bennett Sr. received a genetically modified pig heart transplant during an eight-hour operation on Friday January 7 at the University of Maryland Medical Center, which issued a statement last night. The operation was a last resort for Bennett, 57, who was deemed unfit to have a heart transplant. He was hospitalized for more than six weeks before the operation with life-threatening arrhythmia. “She is dead or buried,” he told reporters. “I want to live. I know I’m shooting in the dark, but that’s my final decision.

Route: Ten genes in the donating pig were modified prior to transplantation. Three of these genes are responsible for the rejection of pig organs in humans, so this was eliminated. Six genes were implanted to help regulate the pig’s immune system, and one additional gene was impregnated to inhibit the rapid growth of pig heart muscle.

The Maryland team also used new experimental drugs to weaken the immune system and prevent rejection, as well as new machines that push water through the muscles to ensure the pig’s heart remains strong until the process. The FDA has issued an emergency directive to do so during the New Year in the New York Times.

Next: The number of limbs is high, with about 107,000 people on the U.S. waiting list, 17 of whom die every day, according to the Health Resources and Services Administration, federal agency.

The first results look encouraging to Bennett, who is expected to come out of the heart-lunging machine that relies on him to keep him alive today (January 11). of rejection or disease.

New Limits: Although xenotransplantation, a method of implanting animal or nerve implants in humans, has a long and unpredictable history, new genetic technologies make this possible. The genetically modified pig in last week’s operation was donated by Revivicor, one of several biotechnology companies working to manufacture pig parts for human immunization.

Revivicor was also behind the successful transfusion of swine kidney to the last human patient October, which was very interesting in proving its effective methods. Also Revivicor, a scientist at Harvard George Church founded the company, eGensisis, which is working to use CRISPR genetic modification to keep animal organs active in human placement, although its follow-up time has fallen short.